Form 4: Dogwood Therapeutics Director David Keefer Acquires Stock Options

David R. Keefer, a Director and 10% owner of Dogwood Therapeutics, Inc., reported the acquisition of 420 stock options with an exercise price of $4.80 per share.

Summary

• The reporting person is David R. Keefer, who serves as a Director and 10% Owner of Dogwood Therapeutics, Inc. (DWTX).
• On June 18, 2025, Mr. Keefer acquired a total of 420 stock options (right to buy) in two separate grants of 210 options each.
• Each stock option has an exercise price of $4.80 per share.
• The options become exercisable on June 18, 2026, and have an expiration date of June 18, 2035.
• The underlying security for these options is Common Stock, with each option representing the right to buy one share.
• Following these transactions, Mr. Keefer directly beneficially owns 420 stock options.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as the grant of stock options to a director indicates alignment of interests with shareholders and is a routine compensation event, suggesting continued commitment from key personnel.

Positives

• The acquisition of stock options by a director aligns their interests with those of shareholders, as the options gain value if the company's stock price increases.
• The grant of options can be viewed as a form of incentive compensation, motivating the director to contribute to the company's long-term success.

Future Outlook

This Form 4 filing is a disclosure of an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing is a standard regulatory disclosure of an insider transaction, specifically the grant of stock options to a director. Such grants are common compensation practices across various industries, particularly in growth-oriented sectors like therapeutics, to align management incentives with shareholder value creation.

Related Party Transactions

• The grant of stock options to David R. Keefer, a Director and 10% owner, constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The grant of options to a director can be viewed positively as it aligns the director's financial incentives with the company's stock performance, potentially encouraging decisions that enhance shareholder value.
• Employees: While not directly impacting all employees, such compensation practices for leadership can set a precedent for performance-based incentives within the company.

Next Steps

• The acquired stock options will become exercisable on June 18, 2026, at which point David R. Keefer will have the right to purchase common stock at the exercise price.

Key Dates

Keywords

Dogwood Therapeutics, DWTX, SEC Form 4, Stock Options, Insider Transaction, Director Compensation, Beneficial Ownership